Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma
An. bras. dermatol
;
91(3): 368-371, graf
Article
in English
| LILACS
| ID: lil-787311
ABSTRACT
Abstract Immunosuppressive drugs and biological agents may represent a potential risk of lymphoma development in patients with rheumatoid arthritis. But most cases are diffuse, large B-cell lymphomas. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, a provisional entity in the 2005 WHO-EORTC classification of cutaneous lymphomas, is only described in a limited number of reports. To our knowledge, our case is a rare instance of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma, after associated treatment with methotrexate and etanercept, in a patient with moderate rheumatoid arthritis who had undergone an orchidectomy incorrectly.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Skin Neoplasms
/
Methotrexate
/
Lymphoma, T-Cell, Cutaneous
/
Etanercept
/
Immunosuppressive Agents
Type of study:
Diagnostic study
Limits:
Humans
/
Male
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2016
Type:
Article
Affiliation country:
China
Institution/Affiliation country:
Sun Yat-sen University/CN
Similar
MEDLINE
...
LILACS
LIS